Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934    Date of Report (Date of earliest event reported):  June 28, 2022   AIKIDO PHARMA INC. (Exact name of registrant as specified in its charter)   Delaware   000-05576   52-0849320 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   One Rockefeller Plaza , 11 th Floor New York , NY   10020 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code:  (703) 992-9325   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:    Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   AIKI   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨       Item 8.01 Other Events.   As previously disclosed, on August 10, 2021, Aikido Pharma Inc. (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2).   On June 23, 2022, the Company received a letter from Nasdaq informing the Company that it had regained compliance with Nasdaq Listing Rule 5550(a)(2) because for the last 11 consecutive business days, from June 7 through June 22, 2022, the closing bid price of the Company’s common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers this matter closed.   On June 28, 2022 the Company issued a press release announcing it regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers this matter closed. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference.   Item 9.01. Financial Statements and Exhibits   (d) Exhibits   Exhibit No.   Description       99.1   Press Release, dated June 28,2022. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)   1     SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Dated: June 28, 2022 AIKIDO PHARMA INC.       By:   /s/ Anthony Hayes   Name: Anthony Hayes   Title:  Chief Executive Officer     2